Format

Send to

Choose Destination
J Exp Clin Cancer Res. 2017 Jul 12;36(1):93. doi: 10.1186/s13046-017-0563-8.

Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades.

Author information

1
Department of Neurosurgery of the Second Affiliated Hospital, College of Pharmacy, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
2
Department of Neurosurgery, the Third People's Hospital of Dalian, Non-directly Affiliated Hospital of Dalian Medical University, Dalian, China.
3
Department of Neurosurgery of the Second Affiliated Hospital, College of Pharmacy, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. maxc1978@163.com.
4
Department of Neurosurgery of the Second Affiliated Hospital, College of Pharmacy, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. Zhangbodl@126.com.

Abstract

BACKGROUND:

Glioblastoma multiforme (GBM) is one of the most refractory and palindromic central nervous system (CNS) neoplasms, and current treatments have poor effects in GBM patients. Hence, the identification of novel therapeutic targets and the development of effective treatment strategies are essential. Alantolactone (ATL) has a wide range of pharmacological activities, and its anti-tumor effect is receiving increasing attention. However, the molecular mechanism underlying the anti-GBM activity of ATL remains poorly understood.

METHODS:

The biological functions of ATL in GBM cells were investigated using migration/invasion, colony formation and cell cycle/apoptosis assays. The localization of nuclear factor kappa B (NF-κB) p50/p65 and its binding to the cyclooxygenase 2 (COX-2) promoter were determined using confocal immunofluorescence, a streptavidin-agarose pulldown assay and a chromatin immunoprecipitation (ChIP) assay. IKKβ kinase activity was determined using a cell IKKβ kinase activity spectrophotometry quantitative detection kit and a molecular docking study. LC-MS/MS analysis was performed to determine the ability of ATL to traverse the blood-brain barrier (BBB). The in vivo anti-tumor efficacy of ATL was also analyzed in xenografted nude mice. Western blot analysis was performed to detect the protein expression levels.

RESULTS:

ATL significantly suppressed the growth of GBM in vivo and in vitro. ATL significantly reduced the expression of COX-2 by inhibiting the kinase activity of IKKβ by targeting the ATP-binding site and then attenuating the binding of NF-κB to the COX-2 promoter region. Furthermore, ATL induced apoptosis by activating the cytochrome c (cyt c)/caspase cascade signaling pathway. Moreover, ATL could penetrate the BBB.

CONCLUSIONS:

ATL exerts its anti-tumor effects in human GBM cells at least in part via NF-κB/COX-2-mediated signaling cascades by inhibiting IKKβ kinase activity. ATL, which is a natural small molecule inhibitor, is a promising candidate for clinical applications in the treatment of CNS tumors.

KEYWORDS:

Alantolactone; Blood-brain barrier; Cox-2; Glioblastoma multiforme; IKKβ/NF-κB

PMID:
28701209
PMCID:
PMC5508758
DOI:
10.1186/s13046-017-0563-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center